- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PROMIMIC Aktie jetzt für 0€ handeln | |||||
| 06.05. | Curiteva & Promimic - Bonded by Innovation | 164 | ACCESS Newswire | HUNTSVILLE, ALABAMA / ACCESS Newswire / May 6, 2025 / Curiteva, a leader in 3D-printed Trabecular PEEK implant technology, is pleased to announce an expanded partnership with Promimic, pioneers in nanotechnology... ► Artikel lesen | |
| 18.02. | Karolinska Development AB (publ): Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface | 200 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN, February 18 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic has published positive results showing a reduction of bacterial... ► Artikel lesen |
2 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 90,81 | -0,32 % | Medtronic Spark Scholarship Launches To Help Students From Low-Income Households Globally Pursue Health Tech Careers | Medtronic Spark Scholarship provides financial assistance and access to support services for students pursuing health tech and related degrees NORTHAMPTON, MA / ACCESS Newswire / November 20, 2025 /... ► Artikel lesen | |
| HCA HEALTHCARE | 443,60 | -0,56 % | HCA Healthcare: Wachstumsstrategie und politische Herausforderungen im Fokus | ||
| LANTHEUS | 50,96 | -0,23 % | Lantheus Holdings, Inc.: Lantheus to Present Florbetaben F 18 Data at CTAD 2025 | ||
| ENVISTA | 18,000 | -1,64 % | Envista Holdings Corporation: Envista Reports Third Quarter 2025 Results | BREA, Calif., Oct. 29, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended September 26, 2025."This was another strong quarter... ► Artikel lesen | |
| CAREDX | 15,680 | +1,26 % | CareDx-Studie: Molekulare Tests verbessern Risikoprognose bei Herztransplantationen | ||
| GT BIOPHARMA | 0,650 | 0,00 % | GT Biopharma, Inc. Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials | NAPLES, FL / ACCESS Newswire / November 19, 2025 / Patients battling aggressive blood cancers face limited treatment options and uncertain outcomes. Scientists have increasingly turned to the body's... ► Artikel lesen | |
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports First Quarter Fiscal Year 2026 Results | Reports 21% Increase in ARR to $21.3 Million, Strong Growth in Net Income, Adjusted EBITDA and Operating Cash Flow
HENDERSON, Nev., Nov. 13, 2025 /PRNewswire/... ► Artikel lesen | |
| CARMAT | 0,099 | -100,00 % | CARMAT Provides an Update on the Ongoing Receivership Procedure | A takeover bid within the context of a sales plan has been received by the judiciary administrator
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced... ► Artikel lesen | |
| CHEMOMETEC | 103,30 | -0,29 % | Chemometec A/S: Growth in revenue and operating profit | Trading statement for Q1 2025/26 (1 July - 30 September 2025) Growth in revenue and operating profit Revenue was up by 8% in Q1 2025/26 (11% at constant exchange rates) to DKK 124.6 million from DKK... ► Artikel lesen | |
| ARRAIL GROUP | 0,186 | 0,00 % | ARRAIL GROUP (06639): POSITIVE PROFIT ALERT | ||
| DEVYSER DIAGNOSTICS | 10,080 | -0,59 % | Devyser Diagnostics AB: Devyser advances U.S. clinical strategy with first patient enrolled in Devyser Accept cfDNA study | Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical trial, a key milestone in the company's efforts to bring a targeted next-generation sequencing solution... ► Artikel lesen | |
| POLAREAN IMAGING | 0,001 | 0,00 % | Polarean Imaging PLC - First Xenon Hyperpolariser in Asia | ||
| GENEDX | 167,52 | 0,00 % | GeneDx auf der Jefferies London Konferenz: Strategische Expansion in der Pädiatrie | ||
| PROGYNY | 26,770 | 0,00 % | Progyny, Inc.: New Men's Health Research from Progyny Challenges Conventional Beliefs about Fertility Knowledge and Action | ||
| ALIGNMENT HEALTHCARE | 19,150 | 0,00 % | Alignment Healthcare stock rating upgraded by JPMorgan to Overweight |
Das Unternehmen PROMIMIC AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 1,405 Euro und damit -7,57 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROMIMIC AB finden Sie auf Wallstreet Online.